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We evaluated the usefulness of phosphoenolpyruvate (PEP), a glycolytic intermediate with antioxidative and energy supplementa-
tion potentials, as an organ preservation agent. Using ex vivo mouse liver and kidney of a static cold storage model, we compared
the effects of PEP against organ damage and oxidative stress during cold preservation with those of glucose or N-acetylcysteine
(NAC). Lactate dehydrogenase (LDH) leakage, histological changes, and oxidative stress parameters (measured as thiobarbituric
acid reactive substance and glutathione content) were determined. PEP (100mM) significantly prevented an increase in LDH
leakage, histological changes, such as tubulonecrosis and vacuolization, and changes in oxidative stress parameters during 72h
of cold preservation in mouse liver. Although glucose (100mM) partly prevented LDH leakage and histological changes, no effects
against oxidative stress were observed. By contrast, NAC inhibited oxidative stress in the liver and did not prevent LDH leakage
or histological changes. PEP also significantly prevented kidney damage during cold preservation in a dose-dependent manner,
and the protective effects were superior to those of glucose and NAC. We suggest that PEP, a functional carbohydrate with organ
protective and antioxidative activities, may be useful as an organ preservation agent in clinical transplantation.
1. Introduction
Clinical transplantation, such as liver or kidney transplanta-
tion, is the only life-saving therapy for some severe diseases,
such as end-stage kidney, liver failure, or chronic end-stage
liver diseases. It is important to conserve the condition of
the graft before transplantation because damage of the graft
during cold preservation is one of the major risk factors for
graftdysfunction.Tosolvethis,organpreservationsolutions,
such as Euro-Collins solution and University of Wisconsin
solution, are used [1, 2]. These solutions are generally com-
posed of electrolytes and buffers, with carbohydrates, such2 ISRN Pharmacology
as glucose and trehalose, added to prevent energy loss and
increase the osmotic pressure of the solution. In addition,
to inhibit the generation of reactive oxygen species during
cold preservation and ischemia/reperfusion, antioxidants,
glutathioneandN-acetylcysteine,areaddedtotheUniversity
of Wisconsin solution and ET-Kyoto solution, respectively
[3, 4]. Although these solutions are essential for clinical
transplantation, they have several disadvantages, including
chemical instability and high viscosity. Additionally, they are
not costeffective for short-term storage [5]. Therefore, devel-
opment of a new and effective reagent for organ preservation
is critical.
Phosphoenolpyruvate (PEP), an intermediate of glycol-
ysis and gluconeogenesis, may have attractive biological
functions. PEP can penetrate the cell membrane and transfer
its high-energy phosphate group to ADP to replenish intra-
cellularATPlevels[6].IthasbeenreportedthatPEPimproves
the energy status of the heart [7]a n ds k e l e t a lm u s c l e[ 8]a ft e r
i s c h e m i aa n dt h a to ft h el i v e ra ft e ri s c h e m i a - r e p e r f u s i o n[ 9].
Recently, we demonstrated that PEP has scavenging poten-
tialsagainstreactiveoxygenspecies,suchashydroxylradicals
andhydrogenperoxide,whichcontributetopathophysiolog-
ical damage as inducers of oxidative stress in a diseased state
[10, 11]. We also elucidated that PEP drastically attenuates
cellularinjuryinducedbyhydrogenperoxideand2-deoxy-D-
glucose,aglycolysisinhibitor,intheporcineproximalkidney
tubularcelllineLLC-PK1,humanhepatocytecelllineHepG2
cells, and HeLa cells [10–12]. In addition, we demonstrated
tha tPEPa tten ua testheeleva tionofaminotransferaseleakage
during organ preservation, histological changes, changes in
oxidative stress parameters (measured as thiobarbituric acid
reactivesubstanceandglutathionecontent),andATPcontent
induced by 72h of cold preservation of mouse liver in an
ex vivo cold preservation system [11]. These in vitro and ex
vivo results suggest that PEP is a functional carbohydrate
metabolite with cytoprotective and antioxidative activities
and may be suitable for organ cold preservation in a clinical
transplantation setting. However, it was unclear whether the
organ protective effects of PEP were superior to those of
otherorganpreservationagents,suchasglucoseorNAC,ina
mouse liver ex vivo system or whether PEP could exert organ
protective effects in other organs, such as kidney, during cold
preservation.
Basedonthesefacts,thisstudywasconductedtoexamine
whether PEP can prevent renal damage during cold storage
by quantifying cellular injury and histological changes in a
mousekidneyexvivosystem.Inaddition,toevaluatetheuse-
fulness of PEP as an organ preservation agent, we compared
the protective effects of PEP with those of components used
in organ preservation solutions, such as glucose or NAC.
2. Materials and Methods
2.1. Materials. Sodium phosphoenolpyruvate monohydrate
was kindly donated by Ube Kousan (Yamaguchi, Japan).
A lactate dehydrogenase assay kit was purchased from
ARKRAY, Inc. (Kyoto, Japan). Glucose and NAC were
obtainedfromNacalaiTesque,Inc.,(Kyoto,Japan)andSigma
(St. Louis, MO, USA), respectively. A TBARS assay kit and
BIOXYTECHGSH/GSSG-412werepurchasedfromCayman
Chemical Co. (Ann Arbor, MI, USA) and Percipio Bio-
sciences, Inc. (Manhattan Beach, CA, USA), respectively. All
other reagents and solvents were of reagent grade. Deionized
and distilled biopure grade water was used throughout the
study.
2.2.ExVivoCold-PreservationLiverandKidneyMouseModel.
The ex vivo cold storage liver model was developed as
previously described [11]. Phosphate-buffered saline (PBS,
pH7 .4),1mM,10mM,and100mMPEP ,100mMglucose,and
10mM NAC dissolved in PBS were used as the preservation
solutions. C57BL/6J mice (male, 25–30g, purchased from
CLEA Japan, Inc., Konan, Japan) were used in this study.
Mice were anaesthetized with diethyl ether inhalation, and
thenamidlineabdominalincisionwasmade.Theportalvein
was cannulated using a 26G needle. The systemic circulation
was then perfused with each solution, and the inferior vena
cava was incised. Subsequently, the liver and kidneys were
carefully removed and preserved at 4
∘C for 72h in each
solution. All experimental procedures conformed to the
animalexperimentguidelinesoftheCommitteefortheEthics
on Animal Experiments of Kumamoto University (Approval
number C24-269).
The organ damage was assessed by elevation of LDH
in the preservation solution and histological analysis. The
level of LDH was measured in the samples of the storage
solutionat24,48,and72husingabioanalyzer(SPOTCHEM
EZ SP-4430; ARKRAY, Inc.). After 72h of preservation, the
liver and kidney were used for histological analysis. The
samples were fixed in 10% neutralized buffered formalin,
embedded in paraffin, and sliced (3mm thickness), and the
slides were stained with hematoxylin and eosin. The samples
were photographed and analyzed using a microscope system
(BIOREVO BZ-9000; KEYENCE Co., Osaka, Japan). A liver
andkidneythathadnotbeensubjectedtocoldstorageserved
as a control for the histological analysis.
Oxidativestressparameters,includingthiobarbituricacid
reactive substance (TBARS) and reduced and oxidized glu-
tathione (GSH and GSSG, resp.), in the liver homogenates
were measured. After 72h of cold preservation, the liver
tissue (approximately 50mg) and 500mL of radioimmuno-
precipitation assay (RIPA) buffer were mixed and homoge-
nized under ice-cold conditions. The sample was centrifuged
(1600×g,10min,4
∘C), and the concentrations of TBARS and
total proteins in the supernatant were measured using the
TBARSassaykitandBCAProteinAssayKit,respectively.For
the measurements of GSH and GSSG, the liver tissues were
weighed and mixed with 5% metaphosphoric acid solution at
a1:5ratio(w/v)andhomogenizedunderice-coldconditions.
The sample was centrifuged (1600×g, 10min, 4
∘C), and the
concentrations of GSH and GSSG were measured using a
BIOXYTECH GSH assay kit.
2.3.StatisticalAnalysis. Theresultsareexpressedasthemean
± SEM. Statistical analysis was performed using GraphPad
Prism ver. 5.01 (GraphPad Software, San Diego, CA, USA).ISRN Pharmacology 3
Two-way analysis of variance was performed to examine
the statistical significance of the data. When significant
differences (𝑃 < 0.05) were identified, the data were further
analyzed using Bonferroni’s multiple comparison test.
3. Results
3.1. Effects of PEP, Glucose, or NAC on the Leakage of LDH
in Preservation Media and Histological Changes in Mice
Liver Induced by Cold Storage. The time course of LDH
levels in the preservation solutions is shown in Figure 1(a).
The concentrations of LDH in the preserved solution were
increased with storage time in the PBS groups. The increase
in LDH levels was significantly prevented by treatment with
100mM PEP, which was identified in our previous study as
an adequate dose for mouse liver preservation [11]. Although
thetreatmentwith100mMglucosealsoinhibitedincreasesin
LDHlevels,significantdifferenceswereobservedbetweenthe
glucose and PEP groups undergoing 72h cold preservation.
Treatment with 10mM NAC did not prevent increases in
LDH leakage during cold preservation.
Therepresentativepicturesoftheliverhistologyafter72h
of preservation in each solution are shown in Figure 1(b).
Significant colliquative necrosis of centrilobular hepatocytes,
hypertrophy, vacuolization in middle and peripheral areas
of the lobules, severe disappearance of hepatic cords, and
deranged hepatic lobules that were poorly stained by eosin
were observed in the PBS-preserved mouse liver. These his-
tologicalchangesweredrasticallyattenuatedbythetreatment
of100mMPEP.Althoughthetreatmentwith100mMglucose
also prevented these histological changes, the effect was
inferior to that induced by PEP. Treatment with 10mM NAC
also did not show any effects on these histological changes.
3 . 2 .E ff e c to fP E Po nt h eC h a n g e si nO x i d a t i v eS t r e s sP a r a m -
eters in Liver Homogenates. The changes in oxidative stress
parameters, including an increase in TBARS and a decrease
in the GSH/GSSG ratio, are shown in Figure 2.Th el i v e r
homogenate treated with PBS for 72h showed approximately
a 145% increase in TBARS levels and a 60% decrease in
the GSH/GSSG ratio compared with those of the nonpre-
served fresh liver. Significant decreases were observed in
the oxidative stress parameters in the liver homogenates of
the 100mM PEP group compared with the PBS group. In
contrast, treatment with 100mM glucose did not show any
effects against changes in the oxidative stress parameters
compared with the PBS group. Treatment with 10mM NAC
tended to inhibit changes in the oxidative stress parameters;
a significant difference in the GSH/GSSG ratio was observed
between the NAC group and the PBS group.
3.3. Effect of PEP Treatment on the Kidney Damage dur-
ing Cold Preservation. In addition to the hepatoprotective
effects, we evaluated the renal protective effects of PEP
during cold preservation. The time course of LDH levels in
the preservation solutions is shown in Figure 3. When the
k i d n e yw a sp r e s e r v e dw i t h1 – 1 0 0 m MP E P ,t h ei n c r e a s ei n
LDH was drastically inhibited in a dose-dependent manner
(Figure 3(a)). Significant differences were observed between
t h eP B Sg r o u pa n dt h e1 0 0m MP E Pg r o u pi n4 8a n d7 2h
cold preservation. In addition, a significant difference was
observed in the 10mM PEP group compared with the PBS
g r o u p7 2 ha ft e rc o l ds t o r a g e .A ss h o w ni nF i g u r e3(b),
significant tubulonecrosis, vacuolization, and deranged renal
tissue that was poorly stained by eosin were observed in the
PBS-preserved mouse kidney. In contrast, these histological
changes were reduced by the 100mM PEP treatment.
As shown in Figure 4,w ec o m p a r e dt h ee ff e c t so fP E P
with glucose or NAC against renal damage during cold
preservation. In the 100mM PEP group, no statistically
significant changes in LDH concentrations as a function of
time were observed during cold preservation. In contrast, a
significant increase was observed after 72h of preservation
compared with that after 24h of preservation in the glucose-
treated group. Moreover, a significant increase in LDH
concentrations after 48h and 72h of preservation in the
NAC-containing solution was observed compared with that
24h. Significant differences were observed between the PEP
and glucose groups after 72h of preservation and between
the PEP group and the NAC group after 48h and 72h
of preservation (Figure 4(a)). The histological pictures of
the kidney after 72h of preservation in each preservation
solution are shown in Figure 4(b).Th eh i s t o l o g i c a lc h a n g e s
related to cold preservationwere partiallyreduced by glucose
treatment.IntheNACtreatmentgroup,tissuethatwaspoorly
stainedb yeosinandvacuoliza tionwereobservedintherenal
medulla. Meanwhile, noticeable changes were not observed
in the renal cortex compared with the medulla.
4. Discussion
In this study, we demonstrated that PEP, an intermediate of
glycolysis, markedly inhibited mouse liver and kidney injury
during cold preservation using an ex vivo mouse model as
measured by LDH release and histological examination, and
the organ protective effects were superior to those of glucose
and NAC, components of existing preservation solutions for
clinicalorgantransplantation.TheseresultsindicatethatPEP
c a nr e d u c eo r g a nd a m a g er e l a t e dt oc o l ds t o r a g ea n ds u g g e s t
that PEP is a superior organ preservation agent compared
with existing components.
In the previous study, we demonstrated that PEP can
prevent organ damage and oxidative stress changes induced
by cold preservation in an ex vivo mouse liver model and
an in vitro HepG2 cell model [11]. In addition, we showed
that PEP showed radical scavenging effects against reactive
oxygen and nitrogens, such as hydroxyl radicals, hydrogen
peroxide, and peroxynitrite [10, 11]. Based on these facts, we
considered that the protective effects of PEP against organ
damage (measured by LDH concentration) induced by cold
preservation may be exerted through antioxidative mecha-
nisms. In this study, PEP also prevented both organ damage
and oxidative stress changes induced by cold preservation
in mice liver. However, NAC, a radical scavenger, did not
inhibit organ damage when it could prevent oxidative stress
changes induced by cold preservation. Moreover, glucose4 ISRN Pharmacology
4000
3000
2000
1000
0
L
D
H
 
(
I
U
/
L
)
PBS
PBS + PEP (100mM) PBS + NAC (10mM)
PBS +PEP +Glu +NAC PBS +PEP +Glu +NAC PBS +PEP +Glu +NAC
24h 48h 72h
∗#
∗∗
PBS + glucose (100mM)
∗∗
∗∗
(a)
PBS
PBS + PEP (100mM) PBS + NAC (10mM) PBS + glucose (100mM)
Nonpreserved
(b)
Figure 1: Effects of PEP, glucose, or NAC on mouse liver damage during cold preservation. (a) Changes in LDH concentrations in the
preservation solutions; PBS (𝑛 = 3), PBS + 100mM PEP (𝑛 = 3), PBS + 100mM glucose (𝑛 = 3), and PBS + 10mM NAC (𝑛 = 3).E a c hb a r
represents the mean ± SEM.
∗𝑃 < 0.05 and
∗∗𝑃 < 0.01,c o m p a r e dw i t ht h eP B Sg r o u p .
#𝑃 < 0.05, compared with the PBS + 100mM PEP
group. (b) Histological pictures of the liver 72h after cold preservation. The liver tissues were fixed with 10% buffered formalin, embedded in
paraffin, sectioned, and stained with hematoxylin-eosin. Nonpreserved fresh liver served as a control. Scale bar = 300𝜇m.
attenuated organ damage without the inhibition of oxidative
stress. These results indicate that oxidative stress did not
directlycontributetoorgandamageduringcoldpreservation
in this ex vivo model. In general, the carbohydrate contained
in preservation solutions used for clinical transplantation,
such as glucose or trehalose, may maintain the energy state
and osmotic pressure and protect the organ against cold
preservation [5]. Therefore, the organ protective effects of
PEP may be exerted through the same mechanisms as those
of carbohydrates.ISRN Pharmacology 5
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Figure 2: Changes in oxidative stress parameters, (a) GSH/GSSG ratio and (b) TBARS, in cold-preserved mouse liver. The study group was
divided into five groups as follows: nonpreserved fresh liver, as a control (𝑛 = 3),P B S(𝑛 = 3), PBS + 100mM PEP (𝑛 = 3),P B S+1 0 0m M
glucose (𝑛 = 3), and PBS + 10mM NAC (𝑛 = 3). Seventy-four hours after storage, the liver tissues were homogenized and analyzed. Each
bar represents the mean ± SEM.
∗∗𝑃 < 0.01, compared with the PBS group;
††𝑃 < 0.01, compared with the nonpreserved group;
##𝑃 < 0.01,
compared with the PBS + 100mM PEP group.
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and
∗∗𝑃 < 0.01, compared with the PBS group. (b) Histological pictures of the kidney 72h after cold preservation. The liver tissues were fixed
with 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin-eosin. Nonpreserved fresh kidney served as a
control. Scale bar = 300𝜇m.6 ISRN Pharmacology
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Figure 4: Comparative effects of PEP, glucose, and NAC on mouse kidney damage during cold preservation. (a) Changes in LDH
concentrations in the preservation solutions; PBS + 100mM PEP (𝑛 = 3), PBS + 100mM glucose (𝑛 = 3), and PBS + 10mM NAC (𝑛 = 4).
E a c hb a rr e p r e s e n t st h em e a n± SEM.
#𝑃 < 0.05,
##𝑃 < 0.01, compared with the PBS + 100mM PEP group. (b) Histological pictures of the
kidney72haftercoldpreservation.Thelivertissueswerefixedwith10%bufferedformalin,embeddedinparaffin,sectioned,andstainedwith
hematoxylin-eosin. Scale bar = 300𝜇m.
Glucose has been used for clinical transplantation as a
component of the Euro-Collins solution, a representative
preservation solution. The results of this study indicate
superior effects of PEP compared with glucose against
organ damage induced by cold preservation and suggest
t h eu s e f u l n e s so fP E Pa sa no r g a np r e s e r v a t i o na g e n ti n
clinical transplantation. In addition to the general effects
as a carbohydrate, the antioxidative effects of PEP will be
advantageous when used as an organ preservation agent in
clinicaltransplantation.Intransplantation,coldpreservation
and warm reperfusion of the graft can induce oxidative stress
and lead to dysfunction and acute rejection of the graft [13].
The University of Wisconsin solution contains glutathione
and allopurinol, whereas the ET-Kyoto solution contains
NAC. These preservation solutions seem to achieve better
results than other preservation solutions [14–16]. PEP may
be an attractive substance with the potential to act as both
a carbohydrate and an antioxidant.
In this study, we demonstrated that PEP could protect
the kidney from damage induced during cold preservation,
whichisalsothecasefortheliver.Theseresultsconfirmorgan
protection by PEP and support its usefulness as an organ
preservation solution. To establish the efficacy of PEP as a
componentoforganpreservationsolutions,itisimportantto
clarify whether PEP-containing organ preservation solutions
a r es a f ef o rb o t ht h ea l l o g r a fta n dt h er e c i p i e n t .Th e r e f o r e ,
further basic and clinical studies are warranted.
In summary, PEP drastically attenuated organ damage
induced by cold preservation in ex vivo mouse liver and
kidney models. The organ protective effects of PEP were
g r e a t e rt h a nt h o s eo fg l u c o s eo rN A C ,w h i c ha r ec o m -
ponents of organ preservation solutions. Organ protection
during cold preservation by PEP may be independent of
antioxidative effects. These results suggest that PEP is a
bifunctional carbohydrate metabolite with organ protective
a n da n t i o x i d a n ta c t i v i t ya n dh a st h ep o t e n t i a lf o ru s ea sISRN Pharmacology 7
an agent for organ preservation in a clinical transplantation
setting.
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